Sunday 18 October 2026
Export NUWE’s income statement to Excel — free account
Nuwellis, Inc.
NUWE Healthcare Medical Devices
Nuwellis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.3 million, down 5.38% from fiscal 2024. In the quarter to June 2026, revenue grew 14.1%, EPS grew 98.8% and free cash flow fell 51.6%, each against the same quarter a year earlier.
0.55
0.00
0.00%
Follow NUWE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.06 | 0.25 | 0.15 | 0.34 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(0.17) | (0.70) | (0.40) | (0.89) | |
P/B ratio |
0.00 | 0.82 | 0.46 | 0.72 | |
Price to Tangible BV |
0.00 | 0.86 | 0.00 | 0.00 | |
EV/Sales |
0.06 | 0.46 | 0.49 | 0.45 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.05) | (0.36) | (0.38) | (0.39) | |
EV/FCF |
(0.05) | (0.35) | (0.37) | (0.39) | |
Quick Ratio |
1.36 | 0.98 | 0.85 | 1.20 | |
Current Ratio |
1.97 | 1.56 | 1.71 | 2.04 | |
Net Debt/EBITDA |
1.25 | 0.46 | 0.42 | 1.24 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.98 | 1.26 | 1.03 | 1.11 | |
Operating CF/Net income |
0.66 | 0.69 | 1.25 | (6.71) | |
Capex/Depreciation |
(0.24) | (3.16) | (0.09) | (0.48) | |
Interest Coverage |
(0.52) | — | — | — | |
Research and Development Expense of Revenue |
47.84% | 71.91% | 36.47% | 27.20% | |
Selling, General and Administrative Expense of Revenue |
189.18% | 188.26% | 132.55% | 159.63% | |
Intangible Assets out of Total Assets |
0.01 | 0.02 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1.12% | 1.04% | 0.99% | 0.86% | |
Graham Net Nets |
(5.92) | 0.70 | 1.42 | 1.12 | |
Graham Number |
183.94 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(4,347.05%) | (6,091.06%) | (5,220.16%) | (3,217.95%) | |
Free Cash Flow Yield |
(2,294.18%) | (532.10%) | (911.62%) | (335.69%) | |
Revenue per Share |
10.87 | 40.52 | 123.05 | 92.76 | |
Operating CF per Share |
(17.52) | (52.48) | (153.81) | (131.67) | |
Capex per Share |
(0.05) | (2.02) | 0.61 | (4.10) | |
Free Cash Flow per Share |
(17.57) | (54.50) | (153.20) | (135.77) | |
Cash per Share |
21.64 | 35.13 | 55.08 | 129.46 | |
Shareholders Equity per Share |
(11.29) | 45.01 | 133.50 | 163.51 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(11.29) | 45.01 | 133.50 | 163.51 | |
Free Cash Flow |
(3.18) | (3.23) | (3.02) | (3.24) | |
Working Capital |
3.89 | 2.10 | 2.15 | 3.68 | |
Capital Expenditures |
(0.01) | (0.12) | 0.01 | (0.10) | |
Net Current Asset Value |
(3.27) | 1.54 | 1.70 | 3.14 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.05 | 0.00 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.37 | 1.55 | 1.61 | 1.22 | |
Average Payables |
2.95 | 2.08 | 1.93 | 2.25 | |
Average Inventory |
1.89 | 1.77 | 1.81 | 2.03 | |
Average Assets |
9.16 | 6.98 | 7.99 | 7.36 | |
Average Common Equity |
(5.51) | 3.12 | 4.58 | 3.54 |
Columns are period end dates